Stable gastric pentadecapeptide BPC 157 in the therapy of the rats with bile duct ligation
| Autor: | Lovorka Batelja Vuletic, Marijana Ćorić, Domagoj Drmic, Danijela Kolenc, Nermin Lojo, Antonio Kokot, Ivan Zoricic, Tinka Vidovic, Sven Seiwerth, Marko Sever, Josipa Vlainić, Anita Zenko Sever, Ljiljana Poljak, Predrag Sikiric |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Piecemeal necrosis Liver Cirrhosis Male medicine.medical_specialty Necrosis Bilirubin Apoptosis Gastroenterology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Ascites Hypertension Portal medicine Hepatic Stellate Cells Animals Rats Wistar Ligation Cell Proliferation Pharmacology Inflammation Bile duct business.industry BPC157 bile duct liver fibrosis/cirrhosis portal hypertension rats Proteins Jaundice medicine.disease Peptide Fragments Rats 030104 developmental biology medicine.anatomical_structure chemistry Liver Gastric Mucosa Hepatic stellate cell Portal hypertension Bile Ducts medicine.symptom business Peptides 030217 neurology & neurosurgery |
| Popis: | Recently, stable gastric pentadecapeptide BPC 157 reversed the high MDA- and NO-tissue values to the healthy levels. Thereby, BPC 157 therapy cured rats with bile duct ligation (BDL) (sacrifice at 2, 4, 6, 8 week). BPC 157-medication (10 μg/kg, 10 ng/kg) was continuously in drinking water (0.16 μg/ml, 0.16 ng/ml, 12 ml/rat/day) since awakening from surgery, or since week 4. Intraperitoneal administration was first at 30 min post-ligation, last at 24 h before sacrifice. Local bath BPC 157 (10 µg/kg) with assessed immediate normalization of portal hypertension was given immediately after establishing portal hypertension values at 4, 6, 8 week. BPC 157 therapy markedly abated jaundice, snout, ears, paws, and yellow abdominal tegmentum in controls since 4th week, ascites, nodular, steatotic liver with large dilatation of main bile duct, increased liver and/or cyst weight, decreased body weight. BPC 157 counteracts the piecemeal necrosis, focal lytic necrosis, apoptosis and focal inflammation, disturbed cell proliferation (Ki-67-staining), cytoskeletal structure in the hepatic stellate cell (α-SMA staining), collagen presentation (Mallory staining). Likewise, counteraction includes increased AST, ALT, GGT, ALP, total bilirubin, direct and indirect and decreased albumin serum levels. As the end-result appear normalized MDA- and NO-tissue values, next to Western blot of NOS2 and NOS3 in the liver tissue, and decreased IL-6, TNF-α, IL-1β levels in liver tissue. Finally, although portal hypertension is sustained in BDL-rats, with BPC 157 therapy, portal hypertension in BDL-rats is either not even developed or rapidly abated, depending on the given BPC 157's regimen. Thus, BPC 157 may counteract liver fibrosis and portal hypertension. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|